Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydronidone in Hepatic Fibrosis and Liver Cirrhosis
NCT07343778Phase 3Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydronidone in hepatic fibrosis, Liver cirrhosis (LC), sponsored by Gyre Pharmaceuticals. Started Mar 2026; status: completed.
02
Drugs
hydronidone
03
Conditions
hepatic fibrosisLiver cirrhosis (LC)
Beyond the preview
Go deeper on NCT07343778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343778.